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Abstract
Purpose Evidence suggests that arsenic in drinking water
causes non-malignant lung disease, but nearly all data
concern exposed adults. The desert city of Antofagasta
(population 257,976) in northern Chile had high concen-
trations of arsenic in drinking water ([800 lg/l) from 1958
until 1970, when a new treatment plant was installed. This
scenario, with its large population, distinct period of high
exposure, and accurate data on past exposure, is virtually
unprecedented in environmental epidemiology. We con-
ducted a pilot study on early-life arsenic exposure and
long-term lung function. We present these preliminary
ﬁndings because of the magnitude of the effects observed.
Methods We recruited a convenience sample consisting
primarily of nursing school employees in Antofagasta and
Arica, a city with low drinking water arsenic. Lung func-
tion and respiratory symptoms in 32 adults exposed to
[800 lg/l arsenic before age 10 were compared to 65
adults without high early-life exposure.
Results Early-life arsenic exposure was associated with
11.5% lower forced expiratory volume in 1 s (FEV1)
(P = 0.04), 12.2% lower forced vital capacity (FVC)
(P = 0.04), and increased breathlessness (prevalence odds
ratio = 5.94, 95% conﬁdence interval 1.36–26.0). Expo-
sure–response relationships between early-life arsenic
concentration and adult FEV1 and FVC were also identiﬁed
(P trend = 0.03).
Conclusions Early-life exposure to arsenic in drinking
water may have irreversible respiratory effects of a mag-
nitude similar to smoking throughout adulthood. Given the
small study size and non-random recruitment methods,
further research is needed to conﬁrm these ﬁndings.
Keywords Arsenic  Childhood exposure  Drinking
water  In utero exposure  Lung  Respiratory
Introduction
Millions of people worldwide are exposed to arsenic in
drinking water (Ravenscroft et al. 2009), an established
cause of lung cancer (IARC 2004). Arsenic affects many
body tissues, but the human lung seems particularly sus-
ceptible (NRC 2001). In fact, lung cancer appears to be the
most common cause of death from arsenic in drinking
water (Smith et al. 1992; Yuan et al. 2007). Most lung
carcinogens—including tobacco smoke, asbestos, and sil-
ica—also cause non-malignant respiratory effects. The ﬁrst
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came from the limited investigations of children in Anto-
fagasta, Chile (Borgon ˜o et al. 1977; Zaldivar 1980). More
recently, studies have linked arsenic in drinking water to
lung function, cough, breathlessness, crepitations, chronic
bronchitis, and bronchiectasis (De et al. 2004; Guha
Mazumder et al. 2000, 2005; Guo et al. 2007; Milton and
Rahman 2002; Parvez et al. 2008; von Ehrenstein et al.
2005). Most data, however, involve adults with recent
exposures. The long-term impacts of early-life arsenic
exposures are largely unknown. An ecologic study of
northern Chile found increased lung cancer, bronchiectasis,
and other chronic obstructive pulmonary disease (COPD)
mortality several decades after high in utero and early-
childhood arsenic exposure (Smith et al. 2006). In this
paper, we present a pilot study on adult lung function in
relation to estimated early-life exposure in the same region
using individual-level data.
Materials and methods
Study area
Northern Chile is among the driest places on Earth. Nearly
everyone there obtains water from municipal supplies,
which have arsenic measurements dating back to the 1950s.
The absence of alternative water sources means that peo-
ple’s lifetime arsenic exposures can be estimated simply by
knowing in which cities they lived. In Antofagasta (popu-
lation 257,976), drinking water arsenic concentrations were
about 90 lg/l until 1958, when arsenic-contaminated rivers
were tapped to supply the growing population. Drinking
water concentrations averaged 870 lg/l until the world’s
ﬁrst large arsenic removal plant became operational in May
1970. From then on, concentrations remained below
150 lg/l with few exceptions. Current levels are around
10 lg/l, the World Health Organization guideline (WHO
2004). This unusual exposure scenario created a population
of tens of thousands of people exposed to high levels of
arsenic in utero or as young children but not as adults. By
contrast, the nearby city of Arica (population 193,788) has
always had drinking water arsenic levels around 10 lg/l.
Other cities in northern Chile had variable arsenic levels,
but none approached those of Antofagasta (Ferreccio et al.
2000).
Study design and participants
In this pilot study, we compared lung function and preva-
lence of respiratory symptoms in adults with and without
high early-life arsenic exposures. The exposed population
comprised long-term residents of Antofagasta, while the
unexposed comparison group comprised mostly long-term
residents of Arica. A convenience sample was recruited by
2 local nurse-interviewers in each city, who invited
employees at the major nursing schools (Universidad Ta-
rapaca ´ de Arica and Universidad de Antofagasta) through
personal communication and ﬂiers posted on campus.
Interviews and lung function tests were conducted from
August 11–21, 2008, in a classroom on campus for 3 days
in each city. In total, we enrolled 97 subjects, primarily
administrative staff, custodians, and facility workers. Par-
ticipants were 32–65 years old, such that they would have
been young children or in utero during the high exposure
period in Antofagasta. The study protocol was approved by
the institutional review boards of the University of Cali-
fornia, Berkeley, and the Pontiﬁcia Universidad Cato ´lica
de Chile. All subjects gave written informed consent before
participating.
Interviews
Each participant was administered a structured question-
naire to assess lifetime residential and occupational history
(all jobs or residences occupied C6 months), water source
types (municipal tap water, bottled, other), current medi-
cations, and medical history. Smoking histories included
ages started and quit, years smoked, and average cigarettes
smoked per day. Ever smoking regularly was deﬁned as
smoking cigarettes at least once per week for C1 year, or
20 packs lifetime. Secondhand smoke was deﬁned as
someone smoking regularly in the same room at home or at
work. Indoor air pollution was deﬁned as irritating or vis-
ible smoke, vapors, gases, or dust regularly in the same
room. Subjects were also asked about the types of fuels
used at home. Occupational exposure was deﬁned as ever
being exposed regularly to vapors, dust, gas, or fumes at a
job held for C6 months (Blanc et al. 2005). Standardized
questions were adapted to local Spanish from question-
naires used by the Latin American Project for the Investi-
gation of Obstructive Lung Diseases (PLATINO), the third
U.S. National Health and Nutrition Examination Survey
(NHANES III), and the second European Community
Respiratory Health Survey (ECRHS II).
Questions about respiratory symptoms were adapted
from the British Medical Research Council (Cotes 1987).
Participants were asked, ‘‘Do you often cough when you
don’t have a cold, such as in the mornings in winter?’’
Chronic cough was assessed with the follow-up question,
‘‘Do you cough like this for at least 3 months a year?’’ The
same questions were asked for phlegm. Subjects were also
asked whether they had trouble breathing (1) rarely, (2)
often, or (3) always. Finally, participants were asked
whether they became breathless when (1) hurrying on level
ground or walking up a slight hill, (2) walking with other
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123people of the same age on level ground, or (3) if they had to
stop for breath when walking on level ground at one’s own
pace.
Lung function measurement using spirometry
After height and weight were measured by nurse-inter-
viewers, lung function was assessed according to American
Thoracic Society guidelines (ATS 1995) using an EasyOne
spirometer (NDD Medical Technologies, Zurich, Switzer-
land) in diagnostic mode. The same trained technician used
the same spirometer in Antofagasta and Arica. Subjects
were instructed to take as deep a breath as possible and
then blow as hard and long as possible into the spirometer.
Following a demonstration and practice with the mouth-
piece, they performed tests in a sitting position with active
coaching. The main lung function values assessed were
forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC). The maneuver was repeated until the
EasyOne indicated satisfactory results were achieved (e.g.,
FEV1 and FVC within 200 ml of previous values) or the
participant chose to stop. Each subject’s best trial (largest
sum of FEV1 and FVC) was included in analyses. Spi-
rometry data were reviewed by a pulmonologist (JB).
Arsenic exposure assessment
Municipal drinking water records used in previous studies
(Ferreccio et al. 2000; Smith et al. 2006) were linked with
each participant’s residential history to obtain age-speciﬁc
estimates of arsenic exposure. The drinking water database
included over 15,000 arsenic measurements in Antofagasta
and11othercitiesinnorthernChilebetween1962and1990,
when concentrations transitioned from high to low. In initial
analyses, high exposure in early life was deﬁned as drinking
water containing [800 lg/l arsenic before age 10. The
unexposed group included mostly long-term residents of
Arica. In our main analyses, the unexposed group also
included eight subjects who either moved to Antofagasta
(from lower exposure areas) after age 10 or who lived in
Antofagasta but were over age 10 during the high exposure
period. Sensitivity analyses were conducted to evaluate
whether changing cut-offs deﬁning ‘‘high exposure’’ (e.g.,
800, 200, or 50 lg/l) and ‘‘early-life’’ (e.g., in utero, 10, or
18 years old) had any impact on results. Exposure–response
was assessed both by using early-life arsenic concentration
as a continuous variable in models and by stratifying sub-
jects into low, medium, and high exposure categories.
Statistical methods
We analyzed data using SAS 9.2 (SAS Institute Inc., Cary,
NC). Student’s t-tests were used to compare the means of
continuous variables. We conducted one-tailed tests of sig-
niﬁcance for pulmonary outcomes because of the clear
direction of a priori hypotheses regarding arsenic. Otherwise,
two-tailed tests were used. Lung function mean residuals
(observed values minus age-, sex-, and height-predicted val-
ues) and percentages (observed values divided by predicted
values) were calculated for subjects with and without high
early-life arsenic exposure. Predicted values for northern
Chile were not available, so we used those of Mexican
AmericansinNHANESIII(Hankinsonetal.1999).Theseare
within 3% of reference values obtained from the PLATINO
study of 5 large Latin American cities (Perez-Padilla et al.
2006). The choice of reference was not critical because our
purpose was to compare arsenic exposed and unexposed, for
whom the same reference values were used.
Both univariate and multivariate models were per-
formed. We did not enter age, sex, or height in the multi-
variate models of lung function because ‘‘unadjusted’’
values were residuals and percentages of age-, sex-, and
height-predicted values. Final linear models adjusted for
ever regularly smoking and variables that were both (1)
associated with pulmonary function in other studies and (2)
different between the arsenic-exposed and arsenic-unex-
posed groups in this study (Table 1). These were entered
dichotomously: childhood secondhand tobacco smoke
(Moshammer et al. 2006); wood, charcoal, or kerosene fuel
use in childhood home (Fullerton et al. 2008); occupational
air pollution (Blanc et al. 2009); and university graduation,
as an indicator of socioeconomic status (Prescott and
Vestbo 1999). Adjusted differences between arsenic-
exposed and arsenic-unexposed subjects were similar
(within 2% predicted FEV1) when potential confounders
were entered as continuous variables (e.g., cigarettes per
day, age started smoking) or multiple indicator variables
(e.g., for education: (1) graduating high school, (2) some
post-high school, (3) graduating university). Adjusting for
outdoor air pollution, adult secondhand smoke, prior diag-
nosis of respiratory illness including pulmonary tuberculo-
sis, obesity (BMI[30 kg/m
2) at time of interview, number
of spirometry maneuvers attempted, or having reproducible
spirometry (difference between highest 2 FEV1 and FVC
values B200 ml) likewise had little impact on results.
Prevalence odds ratios (PORs) for respiratory symptoms
were calculated using the Wald method of logistic regres-
sion. Adjusted models included the same variables used for
spirometry outcomes, plus age (in years) and sex.
Results
As expected, participants reported nearly exclusive use of
municipal sources in this desert region. Of the 32 subjects
exposed to[800 lg/l arsenic in drinking water before age
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12310, half were exposed in utero. The rest were either born
before the peak exposure period began, or moved into the
area after they were born. Of the 65 ‘‘unexposed’’ subjects,
20 drank water with 50–250 lg/l arsenic before age 10. No
subject’s highest drinking water arsenic concentration was
between 250 and 800 lg/l.
Table 1 shows demographic and descriptive character-
istics of participants. Subjects exposed to [800 lg/l
arsenic in drinking water before age 10 were more likely to
have ever smoked regularly (75 vs. 62% of subjects with-
out high early-life exposure), averaged more cigarettes per
day (4.2 vs. 3.4), and started smoking earlier (17.6 vs.
20.2 years old). Additionally, more exposed subjects
reported childhood secondhand smoke (38 vs. 17%) and
fewer of them graduated university (6 vs. 32%). On the
other hand, they reported less secondhand smoke currently
(9 vs. 20% of unexposed), less occupational exposure to
vapors, dusts, gases or fumes (16 vs. 42%), and less wood,
charcoal, and kerosene fuel exposure before age 10 (38 vs.
63%). Adjusting for these and other potential confounders
had little impact on associations between arsenic and lung
function (Tables 2, 3, 4). No subjects reported a past
diagnosis of lung or any other type of cancer.
Table 2 shows lung function mean residuals (observed
minus predicted) and percent of age-, sex-, and height-
predicted values. High early-life arsenic exposure was
Table 1 Characteristics of
participants [mean ± SD or
n (%)]
BMI body mass index
a Reported for jobs held
C6 months
b Reported ‘‘irritating or visible
smoke, vapors, gases, or dust
regularly in same room’’
c Reported someone smoking
regularly in same room
d Average per day during
period of regular smoking
e Never smokers counted as
zeroes
f One subject reported both
asthma and tuberculosis
g Rated by EasyOne spirometer
from 0 (no acceptable tests) to 5
(C3 acceptable tests and
difference between highest 2
forced expiratory volume in 1 s
(FEV1) and forced vital capacity
(FVC) values B150 ml)
h Difference between highest 2
FEV1 and FVC values B200 ml
Peak arsenic before age 10 P value
0–250 lg/l
(n = 65)
[800 lg/l
(n = 32)
Female 45 (69%) 18 (56%) 0.21
Age in years 48.9 ± 9.7 48.0 ± 6.2 0.62
Height in centimeters 161.1 ± 8.6 162.3 ± 8.7 0.54
Weight in kilograms 72.2 ± 13.7 72.6 ± 15.6 0.90
Obese (BMI C 30 kg/m
2) 18 (28%) 6 (19%) 0.34
Highest education completed
Less than high school 9 (14%) 5 (16%) 0.89
High school 12 (19%) 8 (25%) 0.53
Technical school or incomplete university 20 (31%) 17 (53%) 0.05
Graduated from university 21 (32%) 2 (6%) 0.003
Data missing 3 (5%) 0 (0%) 0.22
Occupational vapors, dust, gas, or fumes
a 27 (42%) 5 (16%) 0.01
Indoor air pollution reported
b
Ever 13 (20%) 3 (9%) 0.18
Before age ten 9 (14%) 3 (9%) 0.53
Wood, charcoal, or kerosene in childhood home 41 (63%) 12 (38%) 0.01
Secondhand smoke exposure
c
Ever 35 (54%) 16 (50%) 0.60
Currently 13 (20%) 3 (9%) 0.15
Before age ten 11 (17%) 12 (38%) 0.02
Smoking
Ever 40 (62%) 24 (75%) 0.19
Currently 21 (32%) 11 (34%) 0.84
Age started 20.2 ± 5.2 17.6 ± 3.7 0.04
Cigarettes per day ever
d,e 3.4 ± 5.4 4.2 ± 5.1 0.47
Pack-years
e 4.1 ± 8.1 4.9 ± 7.0 0.65
Respiratory illness diagnosed ever
Any
f 8 (12%) 1 (3%) 0.15
Chronic bronchitis 0 (0%) 1 (3%) 0.16
Asthma 5 (8%) 0 (0%) 0.11
Pulmonary tuberculosis 4 (6%) 0 (0%) 0.15
Lung function test quality
Score
g 4.2 ± 1.1 3.8 ± 1.2 0.05
Reproducible results
h 60 (92%) 28 (88%) 0.45
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123associated with a 244-ml decrease in FEV1 (P = 0.06) and
a 310-ml decrease in FVC (P = 0.04). In terms of percent
of predicted values, this was equivalent to 8.0% lower
FEV1 and 7.9% lower FVC (P = 0.05 for both). When
analyses were restricted to the 33 subjects who reported
never smoking regularly, effect estimates remained high
but changed dramatically with adjustment (16.9 and 19.7%
decreases in FEV1 and FVC, respectively; P\0.05 for
both), suggesting unstable results due to the small number
of subjects.
In analyses conﬁned to concurrently assessed Antofag-
asta residents (n = 45), subjects who had either lived
elsewhere or were older than 10 during the high exposure
period served as the ‘‘unexposed’’ reference (n = 12).
Effect estimates were similar, but the smaller sample size
reduced statistical power (8.4 and 7.1% decreases in FEV1
and FVC (P = 0.10 for both)). Results were also similar
when different age and arsenic concentration cut-offs were
used to deﬁne early-life exposure. For example, with early-
life exposure deﬁned as [200 lg/l arsenic before age 18,
adjusted differences in FEV1 and FVC between exposed
(n = 45) and unexposed (n = 52) were 9.5% (P = 0.02)
and 11.7% (P = 0.006) (not shown in tables). Lung func-
tion deﬁcits were similar (within 2% predicted) in analyses
excluding the 9 participants without reproducible spirom-
etry or the participants with the worst and best lung func-
tion (i.e., possible outliers).
Table 3 shows exposure–response relationships between
peak arsenic concentration before age 10 and FEV1 and
FVC, respectively (P trend = 0.03 for both). Participants
Table 2 Lung function residuals (observed minus predicted) and percent of age-, sex-, and height-predicted values (mean ± SD)
All subjects Peak arsenic before age 10 Crude Adjusted
a
0–250 lg/l (n = 65) [800 lg/l (n = 32) Diff. P value Diff. P value
Percent of predicted FEV1 96.0 ± 13.9 88.1 ± 18.3 -7.9 0.01 -8.0 0.05
Percent of predicted FVC 101.9 ± 15.1 94.7 ± 15.3 -7.2 0.02 -7.9 0.05
FEV1 residual (ml) -127 ± 417 -375 ± 611 -248 0.01 -244 0.06
FVC residual (ml) 55 ± 532 -226 ± 614 -280 0.01 -310 0.04
Never smokers (n = 25) (n = 8)
Percent of predicted FEV1 97.7 ± 14.3 90.7 ± 15.1 -7.0 0.12 -16.9 0.02
Percent of predicted FVC 104.0 ± 17.2 93.3 ± 13.1 -10.7 0.06 -19.7 0.03
FEV1 residual (ml) -77 ± 406 -257 ± 414 -180 0.14 -496 0.02
FVC residual (ml) 129 ± 603 -229 ± 427 -359 0.07 -716 0.03
Ever smokers (n = 40) (n = 24)
Percent of predicted FEV1 95.0 ± 13.7 87.3 ± 19.5 -7.7 0.03 -4.7 0.22
Percent of predicted FVC 100.6 ± 13.7 95.2 ± 16.2 -5.4 0.08 -3.7 0.25
FEV1 residual (ml) -158 ± 425 -414 ± 667 -256 0.03 -156 0.22
FVC residual (ml) 8 ± 484 -225 ± 672 -233 0.06 -180 0.20
Women (n = 45) (n = 18)
Percent of predicted FEV1 94.6 ± 12.1 91.8 ± 15.8 -2.8 0.22 -1.7 0.37
Percent of predicted FVC 100.9 ± 14.9 98.7 ± 14.8 -2.2 0.30 -1.6 0.39
FEV1 residual (ml) -153 ± 321 -210 ± 412 -56 0.28 -17 0.45
FVC residual (ml) 11 ± 480 -35 ± 472 -46 0.37 -27 0.44
Men (n = 20) (n = 14)
Percent of predicted FEV1 99.3 ± 17.2 83.5 ± 20.7 -15.8 0.01 -14.2 0.12
Percent of predicted FVC 104.2 ± 15.6 89.6 ± 15.0 -14.6 0.005 -15.8 0.06
FEV1 residual (ml) -66 ± 584 -587 ± 762 -521 0.02 -440 0.15
FVC residual (ml) 153 ± 636 -472 ± 700 -624 0.005 -673 0.07
Diff. difference, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
a Adjusted for smoking, childhood secondhand smoke, wood, charcoal, or kerosene fuel use in childhood home, occupational air pollution, and
education
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123were also stratiﬁed into 3 groups based on highest early-life
arsenic concentration: \50, 50–250, and [800 lg/l. Sub-
jects exposed to 50–250 lg/l and [800 lg/l had 4.6%
(P = 0.18) and 11.5% (P = 0.04) lower FEV1, respec-
tively, than those exposed to \50 lg/l. A similar pattern
was seen for FVC. Effect estimates were similar when 8
subjects exposed to[800 lg/l only after age 10 were put in
the intermediate group or excluded entirely.
Table 4 shows prevalence of respiratory symptoms.
Thirty-eight percent of exposed subjects reported breathless-
ness walking at a group pace compared to 14% of unexposed
(POR = 5.94,95%conﬁdenceinterval(CI)1.36–26.02).The
POR for reporting any breathlessness was 2.53 (95% CI
0.68–9.45). There was little evidence of associations with
chronic cough, phlegm, chronic bronchitis, or ‘‘trouble
breathing,’’ although few subjects reported these symptoms.
Table 3 Exposure response between early-life arsenic and lung function residuals (observed minus predicted) and percent of age-, sex-, and
height-predicted values (mean ± SD)
Peak arsenic before age 10
\50 lg/l (n = 45) 50–250 lg/l (n = 20) [800 lg/l (n = 32)
Percent predicted FEV1 98.2 ± 14.6 91.2 ± 11.0 88.1 ± 18.3
Percent predicted FVC 103.6 ± 16.7 98.2 ± 10.0 94.7 ± 15.3
FEV1 residual (ml) -63 ± 443 -270 ± 314 -375 ± 611
FVC residual (ml) 103 ± 584 -54 ± 380 -226 ± 614
50–250 compared to\50 lg/l [800 compared to\50 lg/l P trend
b
Crude Adjusted
a Crude Adjusted
a Crude Adjusted
a
Diff. P value Diff. P value Diff. P value Diff. P value
Percent predicted FEV1 -7.0 0.03 -4.6 0.18 -10.0 0.005 -11.5 0.04 0.005 0.03
Percent predicted FVC -5.3 0.10 -2.7 0.32 -8.8 0.01 -12.2 0.04 0.008 0.03
FEV1 residual (ml) -208 0.03 -152 0.16 -312 0.006 -335 0.06 0.005 0.03
FVC residual (ml) -157 0.14 -52 0.40 -329 0.01 -429 0.04 0.006 0.02
Diff. difference, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
a Adjusted for smoking, childhood secondhand smoke, wood, charcoal, or kerosene fuel use in childhood home, occupational air pollution, and
education
b Highest known arsenic concentration before age 10 was entered as a continuous variable in linear models
Table 4 Prevalence odds ratios (PORs) and 95% conﬁdence intervals (CIs) for respiratory symptoms
Peak arsenic before age 10 Crude Adjusted
a
0–250 lg/l (n = 65) [800lg/l (n = 32) POR 95% CI P value POR 95% CI P value
Chronic cough 7 (11%) 5 (16%) 1.53 0.45–5.28 0.26 1.30 0.22–7.80 0.39
Chronic phlegm 5 (7%) 2 (6%) 0.80 0.15–4.37 0.38 0.93 0.10–9.01 0.48
Chronic bronchitis 2 (3%) 1 (3%) 1.02 0.09–11.6 0.49 N/A N/A N/A
Trouble breathing
Rarely 16 (25%) 4 (13%) 0.44 0.13–1.44 0.08 1.20 0.25–5.73 0.41
Often 2 (3%) 2 (6%) 2.10 0.28–15.6 0.23 1.01 0.06–17.2 0.49
Breathlessness walking
Fast/uphill 15 (23%) 13 (41%) 2.28 0.92–5.67 0.04 2.53 0.68–9.45 0.08
At group pace 9 (14%) 12 (38%) 3.73 1.37–10.2 0.004 5.94 1.36–26.0 0.009
At own pace 7 (11%) 10 (31%) 3.77 1.27–11.1 0.006 3.89 0.90–16.8 0.03
Any respiratory symptom 20 (31%) 14 (44%) 1.75 0.73–4.20 0.11 2.63 0.78–8.92 0.06
N/A not available (adjustment variables missing for 1 ‘‘yes’’ respondent)
a Adjusted for age, sex, smoking, childhood secondhand smoke, wood, charcoal, or kerosene fuel use in childhood home, occupational air
pollution, and education
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123Discussion
The decreases in FEV1 and FVC and the PORs above 1.0
for breathlessness identiﬁed in this study suggest that early-
life exposure to arsenic in drinking water affects lung
function, and these effects remain many years after ces-
sation of high exposure. Assuming each pack-year smoked
is associated with a 7.4-ml decrease in FEV1 (Dockery
et al. 1988), the decrease in lung function we observed was
similar in magnitude to that of 45 pack-years. To our
knowledge, this is the ﬁrst time a drinking water contam-
inant has been linked to lung function and respiratory
symptoms 4 decades after peak exposure.
The exact mechanisms by which arsenic causes lung
disease are unknown, and further research may be needed
in this area. However, the biological plausibility that
ingested arsenic can cause toxicity to the lungs is supported
by a variety of studies. In rabbits, the species most similar
to humans in terms of arsenic metabolism (NRC 1999),
arsenic has been shown to accumulate in the lung more
than other organs except the liver and kidney, which are the
primary sites of metabolism and excretion (Bertolero et al.
1981; Marafante et al. 1981). Other animal studies show
that the primary metabolite of arsenic, dimethylarsinic acid
(DMA), is retained longer in the lungs than in other tissues
(Kenyon et al. 2008; Vahter et al. 1984). In humans,
ingested arsenic is an established cause of lung cancer
(IARC 2004), and several studies have linked it to non-
malignant respiratory effects including respiratory symp-
toms, pulmonary function, and a 10-fold increase in
radiographically conﬁrmed bronchiectasis (De et al. 2004;
Guha Mazumder et al. 2000, 2005; Guo et al. 2007; Milton
and Rahman 2002; Parvez et al. 2008; Smith et al. 2006;
von Ehrenstein et al. 2005). In fact, increases in human
lung cancer risk are similar whether arsenic is ingested or
inhaled (Smith et al. 2009). This body of research provides
evidence that the human lung is particularly susceptible to
arsenic in drinking water.
Environmental exposures may be particularly harmful in
early life because of rapid organogenesis and differences in
children’s water intake, metabolism, and detoxiﬁcation
(Landrigan et al. 2004). Arsenic is known to cross the
placenta and reach the fetus, and total arsenic levels in
umbilical cord blood and maternal blood are similar
(Concha et al. 1998b; Hall et al. 2007; Vahter 2009).
Several studies have shown that metabolism of arsenic to
its less toxic metabolite, DMA, is increased in pregnant
women (Vahter 2009). However, a recent study of mother–
infant pairs in Bangladesh found that less than half of total
arsenic in cord blood was DMA (Hall et al. 2007). Other
data suggest that arsenic metabolism may differ between
children and adults, but these ﬁndings are not entirely
consistent (Hall et al. 2009). In a study in a highly exposed
region of Argentina, children could not metabolize ingested
inorganic arsenic to DMA as well as adults (Concha et al.
1998a). In utero arsenic exposures have been linked to
reproductive outcomes including stillbirth (Hopenhayn-
Rich et al. 2000; Vahter 2008, 2009; von Ehrenstein et al.
2006) and, in male infants, smaller thymus size and acute
respiratory illnesses (Raqib et al. 2009). In mice, in utero
drinking water arsenic exposure caused irreversible chan-
ges in airway reactivity to methacholine, altered gene and
protein expression (Lantz et al. 2009) and, at concentra-
tions C42,500 ug/l, tumors in the lungs of offspring but not
dams (Waalkes et al. 2007). An ecologic study comparing
the arsenic-exposed city of Antofagasta to other regions of
Chile found that those exposed in early life had higher
death rates from lung cancer (standardized mortality ratio
(SMR) = 6.1, 95% CI 3.5–9.9), bronchiectasis (SMR =
46.2, 95% CI 21.1–87.7), and other COPD (SMR = 7.6,
95% CI 3.1–15.6) in adulthood (Smith et al. 2006). These
studies all support our results linking early-life arsenic
ingestion to long-term respiratory effects.
Our results are consistent with the 2 previously pub-
lished studies of ingested arsenic and lung function in
people with probable adult exposures. In a study involving
31 subjects in Bangladesh, urinary arsenic concentration
(indicative of current exposure) was inversely associated
with percent predicted FEV1 and FVC (Parvez et al. 2008).
In 287 subjects from West Bengal, India, men with arsenic-
caused skin lesions had 256 and 288 ml lower FEV1 and
FVC, respectively, than those without skin lesions or
known high arsenic exposures (von Ehrenstein et al. 2005).
The FEV1 deﬁcits were much smaller in women (64 ml).
We also found much smaller effects in women (17-ml
FEV1 reduction versus 440 ml for men). Other studies have
reported greater arsenic-associated health effects in men
(Marshall et al. 2007; Rahman et al. 2006), perhaps due to
sex-related differences in arsenic metabolism, water intake,
occupational and other exposures (Hertz-Picciotto et al.
1992; Lindberg et al. 2010; Vahter 2009). The greater
effects observed in men in this study were not likely due to
interactions with smoking since larger arsenic-associated
lung function deﬁcits were seen in never smokers, yet men
smoked more than women in terms of the proportion of
ever smokers (71% vs. 63%), pack-years (5.2 vs. 4.0), and
cigarettes per day (4.2 vs. 3.4).
Strengths of our study include the accuracy of data on
past arsenic exposure. In other places with widespread
exposure, the abundance of private wells and other water
sources, coupled with a lack of historical arsenic records,
makes studies of long-term health effects much more dif-
ﬁcult. By contrast, northern Chile has limited water sources
and has arsenic records dating back more than 50 years,
providing a unique opportunity to study the long-term
impacts of exposure. The main limitation of this study is
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123the convenience method of participant recruitment, raising
concerns about inference and interpretation of results.
Although the problem of arsenic in drinking water in
northern Chile has been publicized, most information has
been on cancer. Our experience is that very few people in
the study cities know about the possible role of arsenic in
non-malignant respiratory disease. This suggests that peo-
ple with respiratory problems in Antofagasta (the exposed
city) would not be more likely to participate than people
with respiratory problems in Arica (the unexposed city),
and differential selection is unlikely to account for the
effects we identiﬁed. A second weakness of this study is
that most exposed and unexposed subjects were not
assessed concurrently. However, effect estimates remained
similar in analyses conﬁned to those who were.
Confounding due to smoking is unlikely to account for
the effects identiﬁed in this study for 2 reasons. First,
entering smoking information into multivariate models had
little impact on the association between arsenic and lung
function. Second, to explain the observed 8–12% decrease
in FEV1, virtually all of the arsenic-exposed subjects would
have to have smoked, while all unexposed would have to
have been never smokers. In actuality, the 2 groups had
similar smoking histories, and these Chilean smokers
consumed fewer cigarettes per day than their U.S. coun-
terparts (CDC 2005). Although arsenic-exposed subjects
had slightly less reproducibility of spirometry, less edu-
cation, and more childhood secondhand smoke exposure,
none of these variables were associated with decreased
lung function in this study, and adjusting for them had little
effect on results. The arsenic-exposed and arsenic-unex-
posed cities (Antofagasta and Arica) have historically had
similar air pollution, industry (e.g., no large coal-ﬁred
power plant nearby), trafﬁc patterns (e.g., 1 major high-
way), geography (coastal desert), sociodemographics, and
dietary patterns (INE 2002). Particulate matter of mass
median aerodynamic diameter B10 lm (PM10) measure-
ments, available for the past 10 years, are similar both at
city centers and across neighborhoods of Antofagasta
(mean 40.4, range 29.7–51.9 lg/m
3) and Arica (mean 40.9,
range 32.5–48.6 lg/m
3). Nitrogen dioxide (NO2) levels are
low in both cities, with annual averages around 8–12 lg/
m
3 (CENMA 2008; SETEC 2008). Although some arsenic
exposures in this area also occur through air and food, these
are minor compared to drinking water (Ferreccio and
Sancha 2006). Except for the nearly 100-fold contrast in
past arsenic exposure, the 2 cities appear similar in all
covariates related to lung function. Although confounding
cannot be completely ruled out, it seems unlikely that some
unknown confounder could cause the lung function
decrements observed in subjects with high early-life
arsenic exposures, similar in magnitude to decades of
heavy smoking.
Federal and state regulations in the United States man-
date protection of susceptible subgroups such as pregnant
women and children. Without relevant studies, however,
the U.S. Environmental Protection Agency has been unable
to incorporate data on the long-term health effects of early-
life exposures into any of its drinking water standards
(Landrigan et al. 2004). A lack of epidemiologic data is
particularly problematic for addressing environmental
exposures such as arsenic, for which there are major dif-
ferences between humans and laboratory animals in
metabolism, co-exposures, and potency (NRC 2001).
Several human studies have assessed the impacts of early-
life environmental exposures, but these have typically
involved short follow-up periods, small numbers of study
subjects, or small effect sizes. For example, dioxins in
breast milk were linked to a lower FEV1/FVC ratio in
Danish children (mean age 8.2 years), but the sample size
was only 29 (ten Tusscher et al. 2001). In a meta-analysis
involving 53,879 children, parental smoking was linked to
respiratory symptoms, but relative risks were generally low
(around 1.15) (Pattenden et al. 2006). In a subsample of
22,712 of these children with valid lung function data,
maternal smoking during pregnancy was linked to a 1%
decrease in FEV1 and essentially no change in FVC
(Moshammer et al. 2006). In a longitudinal study on out-
door air pollution in southern California, the mean differ-
ence in FEV1 growth from age 10 to 18 between the most
exposed city (PM10 = 68 lg/m
3) and the least exposed city
(PM10 = 17 lg/m
3) was 82 ml. Similar effects were seen
for PM2.5,N O 2, and acid vapor (Gauderman et al. 2004). In
the current study, we observed 4-fold larger FEV1 decre-
ments (335 ml) nearly 40 years after high arsenic expo-
sures ended.
Conclusions
This study provides the ﬁrst evidence that in utero and
childhood exposure to arsenic in drinking water is associ-
ated with long-term lung function deﬁcits and shortness of
breath in humans. The magnitude of the decrease in both
FEV1 and FVC suggests that early-life arsenic exposure
could have effects similar to smoking throughout adult-
hood and greater effects than secondhand smoke or air
pollution. Nonetheless, certain potential biases—especially
those related to non-random selection of subjects—were
not controlled for and cannot be excluded. These results
should be conﬁrmed in a larger study with participants who
are representative of the source population. A larger study
could also investigate the effects of lower exposures as well
as effect modiﬁcation and confounding by factors such as
diet, occupational exposures, smoking, and gender. The
public health importance lies in the enormous morbidity
598 Int Arch Occup Environ Health (2011) 84:591–600
123and mortality associated with respiratory effects of this
magnitude, the millions of children with high exposures
worldwide, and the need to incorporate data on early-life
susceptibility into environmental policy.
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